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Background: Using first-pass MRA (FP-MRA) spatial resolution is limited by breath-hold duration. In addition, image
quality may be hampered by respiratory and cardiac motion artefacts. In order to overcome these limitations an
ECG- and navigator-gated high-resolution-MRA sequence (HR-MRA) with slow infusion of extracellular contrast
agent was implemented at 3 Tesla for the assessment of congenital heart disease and compared to standard
first-pass-MRA (FP-MRA).
Methods: 34 patients (median age: 13 years) with congenital heart disease (CHD) were prospectively examined
on a 3 Tesla system. The CMR-protocol comprised functional imaging, FP- and HR-MRA, and viability imaging.
After the acquisition of the FP-MRA sequence using a single dose of extracellular contrast agent the motion
compensated HR-MRA sequence with isotropic resolution was acquired while injecting the second single dose,
utilizing the timeframe before viability imaging. Qualitative scores for image quality (two independent reviewers) as
well as quantitative measurements of vessel sharpness and relative contrast were compared using the Wilcoxon
signed-rank test. Quantitative measurements of vessel diameters were compared using the Bland-Altman test.
Results: The mean image quality score revealed significantly better image quality of the HR-MRA sequence
compared to the FP-MRA sequence in all vessels of interest (ascending aorta (AA), left pulmonary artery (LPA), left
superior pulmonary vein (LSPV), coronary sinus (CS), and coronary ostia (CO); all p < 0.0001). In comparison to FP-
MRA, HR-MRA revealed significantly better vessel sharpness for all considered vessels (AA, LSPV and LPA; all
p < 0.0001). The relative contrast of the HR-MRA sequence was less compared to the FP-MRA sequence (AA: p
<0.028, main pulmonary artery: p <0.004, LSPV: p <0.005). Both, the results of the intra- and interobserver
measurements of the vessel diameters revealed closer correlation and closer 95 % limits of agreement for the HR-
MRA. HR-MRA revealed one additional clinical finding, missed by FP-MRA.
Conclusions: An ECG- and navigator-gated HR-MRA-protocol with infusion of extracellular contrast agent at 3 Tesla
is feasible. HR-MRA delivers significantly better image quality and vessel sharpness compared to FP-MRA. It may be
integrated into a standard CMR-protocol for patients with CHD without the need for additional contrast agent
injection and without any additional examination time.
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Cardiovasculars magnetic resonance (CMR) has become
the main imaging modality for the assessment of congenital
heart disease (CHD) in patients in whom echocardiography
is limited because of a restricted acoustic window. Further-
more, magnetic resonance angiography has become a
mainstay of CHD imaging, because it allows for accurate
non-invasive assessment of the arterial and venous thoracic
vasculature. At present, standard first-pass(FP)-MRA of the
thoracic vasculature is performed using an extracellular
contrast agent and a single or multiphase FP-MRA se-
quence. FP-MRA is performed without cardiac gating and
during one breath-hold [1,2]. Consequently, spatial reso-
lution is limited by breath-hold duration and cardiac mo-
tion artefacts may lead to vessel blurring.
Recent studies at 1.5 Tesla (T) have shown that
the extended plasma half-life of a blood-pool contrast agent
(BP-CA) allows for high-resolution respiratory navigator-
and ECG-gated MRA (HR-MRA) during the steady state
thereby overcoming the aforementioned limitations. In
comparison to FP-MRA, both image quality and vessel
sharpness were significantly improved using the gated HR-
MRA approach [3]. However, blood-pool contrast agents
do not allow for viability imaging. At the same time, the
value of viability imaging in CHD patients has been demon-
strated and it has now become an integral part of CMR im-
aging of CHD at most institutions today [4,5].
Contrast enhanced CMR benefits from a transition to
a higher field strength due to an almost unchanged T1-
relaxivity for extracellular contrast agents and an
increased T1-relaxivity for stationary tissue, resulting in
a higher contrast to noise ratio (CNR) [6]. Taking advan-
tage of the higher CNR, a recent study demonstrated the
feasibility of coronary MRA during slow infusion of an
extracellular contrast agent at 3 Tesla [7].
We hypothesize that a high-resolution respiratory
navigator- and ECG-gated MRA technique using an
extracellular contrast agent during slow infusion at 3
Tesla may be used for imaging of the thoracic vascu-
lature while still allowing for viability imaging.
Thus, the aim of the study was to implement an HR-
MRA-protocol covering the entire thoracic vasculature
using a standard extracellular contrast agent (Gadobu-
trol) and to compare it to a standard FP-MRA sequence
in patients with CHD.
Methods
Study population
Patients with CHD were consecutively enrolled in this
prospective study. Patients with contraindications to
CMR [8], however, were excluded. The study protocol
was approved by the local institutional review board. All
patients or their respective legal guardians gave their
written informed consent.CMR protocol
The studies were performed using a clinical whole-body
3.0 T scanner (Achieva Tx, Philips Healthcare, Best, the
Netherlands) with a maximum gradient amplitude of
80 mT/m and a maximum slew rate of 200 (mT·m-1)/
ms. For signal reception, a 6-channel cardiac phased-
array surface coil was used. All patients were examined
in the supine position. Before the examination, a 20-
gauge intravenous catheter was placed in an antecubital
vein to allow for contrast medium injection. Depending
on the age of the individual patient, the examinations
were performed under general anaesthesia.
The MRA sequences were part of a standard protocol
for the evaluation of CHD. The FP-MRA was performed
after acquisition of functional cine images in the stand-
ard cardiac axes, as well as flow measurements if neces-
sary. Immediately after acquisition of the FP-MRA, the
HR-MRA was obtained during the waiting period for the
delayed enhancement sequence. Therefore, the overall
examination time was not increased.
For the multiphase FP-MRA, a standard T1-weighted
3D gradient echo sequence with a centric ordered k-
space acquisition (CENTRA) scheme in both slice- and
phase-encoding direction was used. The sequence was
acquired during breath-hold and started after injection
of gadobutrol at a dose of 0,1 mmol/kg bodyweight
and at a rate of 1,5 ml/s, followed by a 20 ml saline
flush using the same injection rate. For the injection a
commercial power injector (Spectris, Medrad, Volkach,
Germany) was used. Detailed sequence parameters were
as follows: TR/TE = 5.0/1.66; flip angle = 30°; 4 mm cor-
onal overcontiguous partitions were reconstructed to 60
contiguous 2 mm slices; acquisition matrix = 240 x 240;
field of view (FOV) = 360 mm, resulting in an acquired
in-plane resolution of 1.5 x 1.5 mm.
The isotropic HR-MRA was initiated during injection of
gadobutrol at a dose of 0.1 mmol/kg bodyweight and at a
rate of 0.3 ml/s, followed by a 20 ml saline flush using the
same injection rate. The HR-MRA consisted of a single-
phase T1-weighted 3D inversion recovery sequence. Initial
tests before initiation of the study revealed that an inver-
sion time (TI) of 280 ms revealed the most sufficient back-
ground suppression while still maintaining an overall high
signal. The pulse sequence was ECG-gated to end-diastole
to minimize cardiac motion. The k-space acquisition
scheme was “high-low”. Depending on the patients0 heart
rate, the acquisition time was set between 100–120 ms.
Respiratory navigator gating was used for data acquisition
during free breathing. Additional imaging parameters
were as follows: TR/TE 3.2/1.05 ms, flip angle = 20°,
2.4 mm coronal overcontiguous partitions were recon-
structed to 80 contiguous 1.2 mm slices; acquisition
matrix 300 x 298, FOV = 360 mm, yielding an acquired in-
plane resolution of 1.2 x 1.2 mm.
Table 1 Indication for CMR
Indication for CMR Number
of patients
Follow up of tetralogy of Fallot 6
Follow up of aortic isthmus stenosis 5
Follow up of transposition of the great arteries 3
Follow up of double outlet right ventricle 3
Follow up of common arterial trunk 2
Loeys-Dietz/Marfan-syndrome 3
Follow up of aortal valve stenosis 2
Pulmonary stenosis 2
ASD/VSD 2
Follow up of pulmonary atresia 1
Left atrial appendage aneurysm 1
Follow up of patent ductus arteriosus 1
Ebstein anomaly 1
Other 2
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MRA-images were evaluated separately by two experi-
enced readers (View Forum 5.22, Philips, Best, the
Netherlands) regarding image quality and additional
clinical findings. Both readers were aware of the main
diagnosis and major surgical procedures in each patient,
but were blinded to the results of the second reader. FP-
MRA and HR-MRA were evaluated on separate days
(≥ 7 days between measurements).
Image quality
Vessels of interest were the aortic arch (AA), left super-
ior pulmonary vein (LSPV), left pulmonary artery (LPA),
coronary sinus (CS), and coronary ostia (CO). Image
quality was rated using maximum intensity projections
(MIPs) of both types of MRA based on a five-point grad-
ing scale with respect to image artefacts (e.g. breathing
artefacts and cardiac motion artefacts) and anatomic de-
lineation (i.e. border definition). The rating scale was as
follows: 1) excellent image quality (no artefacts, good de-
lineation of the vessel border); 2) above average image
quality (very few artefacts, very little blurring of the ves-
sel border); 3) average image quality (some artefacts,
some vessel blurring); 4) poor image quality (severe arte-
facts, severe blurring of the vessel border); 5) non diag-
nostic image quality.
Quantitative analysis
Vessel sharpness, relative contrast, and intraobserver
measurements (≥ 7 days between measurements) were
performed by the first reviewer. Measurements of vessel
diameters for the assessment of interobserver variability
were performed by the first and second reviewer.
Vessel sharpness
In order to determine vessel sharpness, an intensity profile
along a specified segment in both types of MRA of the rep-
resentative vessels was created with a public domain image
processing software (ImageJ, U.S. National Institutes of
Health, Bethesda, Maryland). The distance between 20%
and 80% of maximum intensity was measured for each side
of the vessel and then averaged. The reciprocal of the aver-
aged distance was taken as sharpness, where a greater value
is consistent with a better vessel definition.
Relative contrast
Parallel imaging, employed for both MRA sequences did
not allow for absolute quantitative measurements of
signal- and contrast-to-noise. Therefore, contrast ratios(RC) between vessels (SV) and signal in the surrounding
tissue (ST) were calculated based on the following for-
mula: RC ¼ SVSTð ÞSVþSTð Þ
Regions of interest (> 100 mm2) were placed in the re-
spective vessels (AA, main pulmonary artery (PA), LSPV)
and the adjacent tissue. The dynamic phase exhibiting the
strongest enhancement in the vessel of interest was chosen
for the FP-MRA measurements. For both, the FP- and the
HR-MRA, identical locations for the measurements were
chosen.
Inter- and intraobserver agreement
Cranio-caudal and anterior-posterior diameters of AA,
LPA, and LSPV were measured in both, FP- and HR-
MRA sequences.
Statistical analysis
The data analysis was performed using commercially avail-
able software (Analyze-it for Microsoft Excel v. 2.12;
Analyze-it Software, London, UK). All data are given as
mean ± standard deviation (SD). Qualitative scores for
image quality as well as quantitative measurements of ves-
sel sharpness and relative contrast were compared using
the Wilcoxon signed-rank test. Quantitative measurements
of vessel diameters were compared using the Bland-Altman
test in order to evaluate agreement.
Results
A total of 34 patients (18 male, 16 female) with a mean
age of 18,1 years (median 13 years) were enrolled in the
study (Table 1). The study protocol was successfully
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sequence was 15 seconds per dynamic scan (a total of
three dynamics was acquired). The mean duration of the
HR-MRA sequence was 2 minutes and 18 seconds ±
29 seconds (range from 1:38 to 3:40 minutes).Image quality
The mean image quality score, independently rated by
both reviewers, revealed significantly better image qual-
ity of the HR-MRA sequence compared to the FP-MRA
sequence in all vessels of interest (p < 0.0001):
AA: FP-MRA 2.78 ± 0.48 (median: 3; range: 2–4) vs.
HR-MRA 2.26 ± 0.62 (median: 2; range: 1–4), LSPV: FP-
MRA 3.19 ± 0.50 (median: 3; range: 2–4) vs. HR-MRA
2.38 ± 0.62 (median: 2; range: 1–4), LPA: FP-MRA
3.06 ± 0.46 (median: 3; range: 2–4) vs. HR-MRA 2.47 ±
0.61 (median: 2; range: 2–4); CS: FP-MRA 3.84 ±
0.68 (median: 4; range: 3–5) vs. HR-MRA 2.50 ± 0.74
(median: 2; range: 2–5) and CO: FP-MRA 4.47 ±
0.63 (median: 5; range: 3–5) vs. HR-MRA 3.10 ± 1.01
(median: 3; range: 2–5).
Typical examples demonstrating the superior image qual-
ity of HR-MRA compared to FP-MRA are given in Figures 1,
2, and 3. HR-MRA revealed one clinical finding that was
missed by FP-MRA: Due to cardiac motion, an abnormal
offspring of the left coronary artery could only be
detected by HR-MRA (Figure 3).Figure 1 10-month-old patient with ventricular septal defectVessel sharpness
In comparison to the FP-MRA sequence, the HR-MRA
sequence revealed a significantly better vessel sharpness
for all considered vessels:
AA: FP-MRA: 0.49 ± 0.09 vs. HR-MRA: 0.70 ± 0.13,
LSPV: FP-MRA: 0.38 ± 0.10 vs. HR-MRA: 0.58 ± 0.12,
LPA: FP-MRA: 0.36 ± 0.06 vs. HR-MRA: 0.51 ± 0.12 (all
p < 0.0001).(arrow), persistent left superior vena cava, bilateral atelectasis
and bovine arch. FP-MRA (A-D) and HR-MRA (E-H) in coronal (A,E),
axial (B,F,D,H) and sagittal plane (C,G).Relative contrast
The relative contrast of the HR-MRA sequence was less
compared to the FP-MRA sequence:
AA: FP-MRA: 0.84 ± 0.06 vs. HR-MRA: 0.81 ± 0.07
(p <0.028), PA: FP-MRA: 0.87 ± 0.05 vs. HR-MRA: 0.84
± 0.06 (p <0.004), LSPV: FP-MRA: 0.86 ± 0.06 vs. HR-
MRA: 0.83 ± 0.06 (p <0.005).Intra- and interobserver agreement
Both, the results of the intra- and interobserver mea-
surements of the vessel diameters revealed much closer
95% limits of agreement and higher correlation coeffi-
cients for the HR-MRA sequence in comparison to the
FP-MRA sequence (Figure 4).Discussion
Cardiac CMR, especially as a postoperative follow up
modality, has become the primary diagnostic imaging
tool for CHD patients. Not only because it is the gold
standard for the evaluation of left and right ventricular
function, but also because it allows for reliable assess-
ment of vascular structures independent of an acoustic
window. While recent studies have mostly focused on
increasing the temporal resolution of MRA in patients
with CHD [9,10], imaging issues related to motion arte-
facts (respiratory and cardiac motion) have yet not been
fully addressed. Especially in children and diseased
Figure 2 11-year-old patient after surgical correction of a
common arterial trunk. FP-MRA (A-C) and HR-MRA (D) in coronal
plane. Note the insufficiency jet of the aortic valve (arrow). En face
view of the arterial truncal valve with three leaflets in FP- (E) and
HR-MRA (F).
Figure 3 11-year-old patient after surgical correction of a
common arterial trunk (same patient as in Figure 2). Axial plane
through the ascending aorta at the level of the coronary ostia in
FP-MRA (A) and HR-MRA (B). Whereas in the FP-MRA only the
origin of the right coronary artery can be detected (thin arrow),
the HR-MRA accurately depicts the origins of both coronary arteries
(thin arrow: right coronary artery; thick arrow: left coronary artery)
revealing an abnormal origin of the left coronary artery out of the
non-coronary cusp.
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ity of FP-MRA.
The combination of ECG- and respiratory navigator-
gated MRA using a blood-pool contrast agent at 1.5 T
has shown to overcome these limitations [3]. However,
blood-pool contrast agents are of higher costs and even
more importantly, they exclude the possibility of viability
imaging. Studies have revealed the value of viability im-
aging in patients after surgery of CHD as the presence
of scar or fibrous tissue could be related to adverse
ventricular mechanics and a higher prevalence of non-
sustained ventricular tachycardia [4,5].
Thus, an ideal imaging protocol for the assessment
of complex congenital heart disease should not only
include functional imaging and MRA but also viability
imaging. In this study, a comprehensive imaging proto-
col was established, which includes functional imaging,
FP-MRA, as well as viability imaging. Adding viabilityimaging does require the injection of a double dose of
contrast agent as well as a waiting period of approxi-
mately 12–15 minutes after contrast injection to allow for
delayed enhancement imaging. The second injection and
waiting period were used to acquire a high-resolution
motion compensated MRA sequence (HR-MRA) at no
cost of additional scan time or contrast agent.
In comparison to the FP-MRA, the HR-MRA
sequence revealed a significantly better image quality
and vessel sharpness (Figures 1, 2, 3). Most likely, these
results could be attributed to the higher resolution as
well as the improved motion compensation through
ECG-gating and navigator respiratory compensation.
Another noteworthy advantage of HR-MRA compared
to FP-MRA is the acquisition of isotropic voxels allow-
ing for multiplanar image reconstruction without any
loss of image resolution (Figure 1, 2). The fact that HR-
MRA revealed an abnormal offspring of the left coronary
artery, missed by FP-MRA in one patient, highlights the
value of isotropic high resolution and motion compensa-
tion (Figure 3). One inherent drawback of the motion
compensated approach is the missing dynamic informa-
tion. Thus, it can only be used as an add on sequence.
However, implementing the HR-MRA into a standard
CHD-CMR-protocol does not involve any additional scan
time or the use of additional contrast agent injection.
Due to the slow injection rate that was used for the
HR-MRA, the relative contrast between the examined
vessels and surrounding tissue in all acquired HR-
sequences was lower compared to the bolus technique
(FP-MRA). Due to the most compact bolus geometry in
the PA during the first-pass, the largest difference be-
tween relative contrasts was found in this vessel.
Intra- and interobserver agreement results revealed
much closer 95% limits of agreement and higher correl-
ation coefficients for the HR-MRA sequence in
Figure 4 Intraobserver method agreement of FP-MRA- (A) and HR-MRA-measurements (B) of reviewer 1. Interobserver method
agreement derived from FP-MRA (C) and HR-MRA (D) measurements of reviewers 1 and 2.
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shows the importance of vessel sharpness rather than
relative contrast for accurate assessment of vessel
diameters.
The MRA sequence employed in this study was similar
to the approach by Naehle et al. [3]. They compared a
first-pass MRA-protocol with a high-resolution motion
compensated steady-state protocol following the injec-
tion of a blood-pool contrast agent (Vasovist) at
1.5 T [11]. The use of a blood-pool agent in their study
did allow them to deliberately choose an inversion time
for optimal suppression of background tissues, whereas
in our study a fixed inversion time had to be used due
to the limited acquisition window after contrast agent
injection. Also, the spatial resolution had to be sacrificed
to allow for faster acquisition of the 3D HR-MRA data-
set. Nevertheless, vessel sharpness of the motion com-
pensated MRA vs. the first-pass-MRA was very similar
in both studies, using the same measurement technique.
Similar to Naehle et al., an additional clinical finding
was also detected by motion compensated MRA which
was missed by FP-MRA, underscoring the value of mo-
tion compensation. Most importantly, the HR-MRAapproach in this study overcomes a major limitation of
the previously published approach as it allows for viabil-
ity imaging and thus fits perfectly into a standard CHD-
CMR-protocol. In addition, contrary to blood-pool con-
trast agents, the contrast agent used in this study has
recently been approved for use in children > 2 years in
North America and Europe.
Previous studies have demonstrated the value of 3D
whole-heart imaging in pediatric populations using
balanced steady-state free precession (b-SSFP) sequences
[12,13]. However, one advantage of the proposed
approach in comparison to b-SSFP is the high CNR,
which is achieved through the use of an IR-pulse sup-
pressing the background signal. In addition, while the
non-contrast enhanced b-SSFP approach has proven to
work at 1.5 T, its use may be limited by artefacts related
to b0 and b1 field inhomogeneity at 3 Tesla.
Another recent study by Yang et al. [7] demonstrated
the feasibility and diagnostic yield of a contrast-
enhanced whole-heart coronary MRA at 3 T using
an extracellular contrast agent (gadobenate dimeglu-
mine) during slow injection. Interestingly, although the
contrast agent in this study (gadobutrol) has an even
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the acquisition of a 3D motion compensated HR-MRA
dataset, covering the entire thorax with an even higher
resolution, was feasible.
Using a fixed TI of 200 ms, Yang et al. achieved an op-
timal suppression of background tissue. In contrast, the
TI chosen in this study was significantly longer for sev-
eral reasons. First, the contrast agent could not be com-
pletely injected as a slow infusion, because a bolus
injection is required for FP-MRA, which in turn results
in a broader variation of contrast agent concentration in
the blood. Second, the albumin binding of gadobutrol
is even less, yielding an even shorter imaging window.
Finally, the heart rate of the patients in this study was
not controlled resulting in a wide range of heart rates.
Thus, we decided to choose a longer TI, which might
not reveal optimal suppression of background tissue but
yields a good overall signal to noise ratio for the majority
of the patients. Moreover for imaging of the entire thor-
acic vasculature, suppression of background signal is less
critical compared to coronary imaging.
Due to variations in patients’ total amount of contrast
agent injected, variation in heart rate, navigator perform-
ance and the subsequent variation of acquisition dur-
ation, it is difficult to determine the optimum contrast
agent injection protocol for the proposed FP/HR-MRA
approach. The use of a bolus for FP-MRA and subse-
quent slow injection of contrast agent has shown to
deliver a good CNR in this study. However, further
research is warranted to determine, whether a further
improvement of CNR can be achieved with a tailored
protocol taking into account the aforementioned variables.Conclusions
In conclusion, it could be shown that an ECG- and navi-
gator-gated HR-MRA-protocol with infusion of extracel-
lular contrast agent at 3 Tesla is feasible. Furthermore, it
delivers significantly better image quality and vessel
sharpness at nearly equivalent contrast compared to FP-
MRA. Therefore, it may be integrated into a standard
CMR-protocol for patients with CHD without the need
for additional contrast agent injection and without any
additional examination time.
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